Summary: In this 52-week single-centre randomised trial of 34 adults with type 2 diabetes, once-weekly subcutaneous semaglutide (1.0 mg) reduced LDL and non-HDL cholesterol and shifted LDL and HDL subfractions toward a less atherogenic profile, alongside reductions in body mass index, waist circumference and HbA1c. Daily oral sitagliptin (100 mg) produced only modest glycaemic improvement without substantial lipid change. Exact between-group effect sizes, 95% confidence intervals and p-values were not reported in the abstract.
PICO Summary
| Element | Detail |
|---|---|
| Population | 34 obese adults with type 2 diabetes; single-centre randomised trial, Hungary. A further 31 age- and weight-matched non-diabetic obese individuals served as controls. |
| Intervention | Subcutaneous semaglutide 1.0 mg once weekly for 52 weeks (n=18). |
| Comparison | Oral sitagliptin 100 mg once daily for 52 weeks (n=16). |
| Outcome | Semaglutide produced significant reductions in body mass index, waist circumference and HbA1c, with reductions in LDL and non-HDL cholesterol and redistribution of LDL and HDL subfractions (Lipoprint gel electrophoresis) toward a less atherogenic profile. Sitagliptin gave modest glycaemic improvement without substantial lipid change. Multivariate regression indicated the subfraction shifts were not driven by changes in body mass index or HbA1c. Exact effect sizes, 95% CIs, p-values and ARR/NNT were not reported in the abstract. |
Expert Commentary
This small mechanistic trial is best read as hypothesis-generating rather than practice-changing. The signal is biologically coherent: semaglutide reduced LDL and non-HDL cholesterol and, more interestingly, redistributed lipoprotein subfractions toward a less atherogenic pattern, with the regression analysis suggesting these shifts were not merely a consequence of weight loss or improved glycaemia. That hint of a direct, pleiotropic lipid effect is the study’s most novel contribution. The principal limitation is scale. With only 34 randomised participants at a single centre, the trial is underpowered for hard lipid endpoints and cannot speak to cardiovascular outcomes; subfraction analysis by Lipoprint is also a surrogate of uncertain prognostic weight. The abstract reports no exact effect sizes, confidence intervals or p-values, so the magnitude of benefit cannot be judged here. Can I use this with my patients? Not yet as a reason to choose semaglutide for lipids specifically. For a patient with type 2 diabetes who already warrants a GLP-1 receptor agonist for glycaemia and weight, these findings are reassuring but not decisive. Larger trials with prespecified lipid endpoints and cardiovascular follow-up are needed before subfraction remodelling informs prescribing.
References
Tóth LI, Harsányi A, Csiha S, Molnár Á, Lőrincz H, Nagy AC, et al. Semaglutide Improves Lipid Subfraction Profiles in Type 2 Diabetes: Insights from a One-Year Follow-Up Study. Int J Mol Sci. 2025;26(13):5951. doi:10.3390/ijms26135951